[1] Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemio, 2016; 40, 39−46. doi:  10.1016/j.canep.2015.10.031
[2] Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2018; 29, iv68−78.
[3] Szucs Z, Thway K, Fisher C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol, 2017; 13, 93−107. doi:  10.2217/fon-2016-0192
[4] Napolitano A, Vincenzi B. Secondary KIT mutations: the GIST of drug resistance and sensitivity. Br J Cancer, 2019; 120, 577−8. doi:  10.1038/s41416-019-0388-7
[5] Ibrahim A, Chopra S. Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors. Arch Pathol Lab Med, 2019; 6.
[6] Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics, 2014; 30, 2114−20. doi:  10.1093/bioinformatics/btu170
[7] Zeng L, Cai C, Li S, et al. Essential Roles of Cyclin Y-Like 1 and Cyclin Y in Dividing Wnt-Responsive Mammary Stem/Progenitor Cells. PLoS Genet, 2016; 12, e1006055. doi:  10.1371/journal.pgen.1006055
[8] Charo LM, Burgoyne AM, Fanta PT, et al. A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy. J Natl Compr Canc Netw, 2018; 16, 238−42. doi:  10.6004/jnccn.2017.7039
[9] Capelli L, Petracci E, Quagliuolo V, et al. Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients – A GIRCG study. Eur J Surg Oncol, 2016; 42, 1206−14. doi:  10.1016/j.ejso.2016.05.022